The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

Dragowska, Wieslawa H; Weppler, Sherry A; Qadir, Mohammed A; Wong, Ling Yan; Franssen, Yannick; Baker, Jennifer HE; Kapanen, Anita I; Kierkels, Guido JJ; Masin, Dana; Minchinton, Andrew I; Gelmon, Karen A; Bally, Marcel B

doi:10.1186/1471-2407-11-420

BMC Cancer

Article metrics
Last updated: Fri, 3 May 2024 19:33:30 Z

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

Access & Citations

7833

Article Accesses
23

Web of Science
18

CrossRef

Citation counts are provided from Web of Science and CrossRef. The counts may vary by service, and are reliant on the availability of their data. Counts will update daily once available.

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com